Zai Lab (ZLAB) Q3 2024 earnings summary

Executive summary

• Net product revenue grew 47% year-over-year in Q3 2024 to $101.8 million, driven by VYVGART, ZEJULA, and NUZYRA, with strong commercial execution and pipeline progress including positive KarXT and ZL-1310 data.

• Net loss improved by 40% year-over-year to $41.7 million, with operational efficiency gains and a focus on profitability by end of 2025.

• Cash and equivalents totaled $716.1 million as of September 30, 2024, supporting ongoing operations and future growth.

• Expanded late-stage pipeline and achieved regulatory milestones, including NMPA approvals for VYVGART Hytrulo (CIDP) and XACDURO.

• Year-to-date 2024 product revenue reached $289.1 million, a 44% increase year-over-year.

Financial highlights

• Q3 2024 net product revenue: $101.8 million (+47% Y/Y); nine-month 2024: $289.1 million (+44% Y/Y).

• VYVGART Q3 revenue: $27.3 million (+458% Y/Y); ZEJULA: $48.2 million (+16% Y/Y); NUZYRA: $10.0 million (+82% Y/Y); QINLOCK: $8.6 million (+52% Y/Y).

• Net loss for Q3 2024 was $41.7 million, a 40% improvement from Q3 2023.

• Adjusted loss from operations: $48.2 million in Q3 2024, down 19% year-over-year.

• Cash position at quarter-end: $716.1 million.

Outlook and guidance

• On track to reach profitability by end of 2025, supported by revenue growth and cost discipline.

• Three product launches in China expected by end of 2024: XACDURO, VYVGART Hytrulo, and AUGTYRO.

• Up to four regulatory submissions to NMPA in next six months, including KarXT NDA for schizophrenia in early 2025.

• R&D and SG&A investments will remain significant to support pipeline and commercial activities.

• 2028 vision includes over $2B revenue and expanding operating margins.